- Home
- MYGN
MYGN
Myriad Genetics Inc.
as 04-01-2025 4:00pm EST
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 1.3B | IPO Year: | 1995 |
| Target Price: | $20.43 | AVG Volume (30 days): | 883.9K |
| Analyst Decision: | Hold | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.53 - $29.30 | Next Earning Date: | 05-06-2025 |
| Revenue: | $837,600,000 | Revenue Growth: | 11.21% |
| Revenue Growth (this year): | 3.03% | Revenue Growth (next year): | 8.31% |
Latest Myriad Genetics Inc. News
MYGN Breaking Stock News: Dive into MYGN Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?
Zacks
7 days ago
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?
Argus Research
7 days ago
MYGN: What does Argus have to say about MYGN?
StockStory
13 days ago
1 Small-Cap Stock on Our Watchlist and 2 to Avoid
StockStory
14 days ago
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
StockStory
16 days ago
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?
MT Newswires
20 days ago
Myriad Genetics Shares Rise After Upgrade From Piper Sandler
StockStory
21 days ago
Why Are Myriad Genetics (MYGN) Shares Soaring Today
Compare MYGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MYGN Myriad Genetics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.